

Synthesis and Anti-inflammatory Activity of Steroidal Isoxazoles

DEVENDER PATHAK* and DHARAM PAUL JINDAL
*University Institute of Pharmaceutical Sciences
Panjab University, Chandigarh-160 014*

The steroidal isoxazoles, 4-aza-5 α -cholestano [3,2-c] isoxazole (2), 4-aza-5 α -androstano [3,2-c] isoxazol-17 β -yl acetate (4) and 17a-aza-D-homo-5-androsteno [17,16-c] isoxazol-3 β -yl acetate (6) have been prepared and screened for their biological activity. The Compound 2 (ED₅₀ = 5.67 mg/kg), Compound 4 (ED₅₀ = 2.97 mg/kg) and Compound 6 (ED₅₀ = 11.00 mg/kg) were found to be potent anti-inflammatory agents.

INTRODUCTION

There continues interest in the heteromodification of steroids. Heteromodification of glucocorticoids has led to the synthesis of several extremely potent anti-inflammatory agents¹⁻⁴. Earlier, it was observed that all the steroidal compounds possessing anti-inflammatory activity have C-3 oxygen function. An attempt was made to synthesise anti-inflammatory agents lacking C-3 oxygen function. In the earlier studies, it was observed that certain pyrazole derivatives possess anti-inflammatory activity where oxygen at C-3 has been replaced with N.⁵⁻⁶ Heterosteroids of medicinal interest have been reported from our research laboratory.⁷⁻¹⁰ Therefore, it was considered worth while to fuse isoxazole moiety to the ring A of the steroid in cholestane series and ring A and D in the androstane series and to screen for their biological activities.

The initial work was carried out in cholestane series. 3-chloro-4-aza-5 α -cholest-2-en-2-aldehyde (1) was prepared by the known procedure.¹¹ It showed a proton singlet at δ 9.80 in the NMR spectrum and showed a UV maximum at 302 nm. Refluxing 1 with hydroxylamine hydrochloride in the presence of potassium carbonate in aldehyde-free ethanol gave the product 2. The NMR spectrum showed a signal at 8.00 ppm for the hydrogen on the heterocyclic ring, *i.e.*, isoxazole ring and showed a UV maximum at 262 nm.

Similar sequence of reactions was carried out for the synthesis of 4-aza-5 α -androstano [3,2-c] isoxazol-17 β -yl-acetate (4). Testosterone acetate was oxidized with permanganate/periodate solution to give the seco-keto acid¹². The acetoxy function was hydrolysed to hydroxy group under these reaction conditions. The seco-keto acid was subjected to the Leukart reaction resulting in the formation of lactam, then acetate was prepared, which on treatment with Vilsmeier-Haack reagent yielded 17 β -acetoxy-3-chloro-4-aza-5 β -androst-2-en-aldehyde (3).¹¹

*Present address: Department of Pharmaceutical Chemistry, Dr. K.N. Modi Institute of Pharmaceutical Education & Research, Modi Nagar-201 204, India.

Refluxing compound 3 with hydroxylamine hydrochloride in the presence of potassium carbonate in aldehyde-free ethanol gave the compound 4. The NMR spectrum showed a signal at 7.87 ppm for the hydrogen on the isoxazole ring and it also showed a UV maximum at 262 nm.


The synthesis of 17a-aza-D-homo-5-androsteno [17,16-c] isoxazol-3 β -yl acetate (6) was then carried out. 3 β -acetoxy-17-chloro-17a-aza-D-homo-5,16-androstadien-16-aldehyde (5) was prepared as reported earlier⁵. Treatment of compound 5 with hydroxylamine hydrochloride under similar conditions yielded the compound 6. The NMR spectrum of compound 6 showed a signal at 8.03 ppm for the hydrogen on the isoxazole ring attached to the D ring of steroidal nucleus and also showed a UV maximum at 265 nm.

The compounds 2, 4 and 6 were stable to alkali. Either of the compounds did not show opening of the isoxazole system on treatment with sodium methoxide which showed that the [3,2-c] system was present instead of [2,3-d] isoxazole in the compounds 2 and 4 and [17,16-c] isoxazole in the compound 6 instead of [16,17-d] isoxazole.

EXPERIMENTAL

The melting points reported are uncorrected. NMR spectra were recorded on a EM-390, 90 MHz model NMR instrument using tetramethylsilane (TMS) as the internal standard. IR spectra were obtained on Perkin-Elmer 137 spectrophotometer in a KBr pellet. Mass spectra were recorded on a Vg micro mass 7070F mass spectrometer. The structures of the compounds were established on the basis of their elemental analysis and spectral data.


4-Aza-5 α -cholestano [3,2-c] isoxazole (2): Potassium carbonate (0.1 g) was added to a refluxing solution of 3-chloro-4-aza-5 α -cholest-2-en-2-aldehyde (1) (0.2 g) in aldehyde-free ethanol (50 mL). After 10 minutes hydroxylamine hydrochloride (0.1 g) was added and refluxed for 2 h. The reaction mixture was concentrated to 10 mL and poured into ice-cold water (100 mL). The precipitate thus obtained was washed thoroughly with water, dried and crystallised from



4-Aza-5 α -Cholestano [3,2-c] isoxazole (2)

acetone to give 2. m.p. 136°C, yield 54.6%. Analysis: found (%) C 78.49, H 11.07, N 6.75, required C 78.58, H 10.75, N 6.80. UV max (MeOH): 262 nm. IR (KBr): 3175 cm^{-1} (N—H stretch), 2880 cm^{-1} (C—H stretch). NMR (CDCl_3): δ 0.70 (s, 3H), 0.93 (s, 3H), 2.97 (m, 1H), 4.13 (1H, disappeared on D_2O exchange) and 8.00 ppm (s, 1H). EIMS: m/z 412 (M^+).


*4-Aza-5 α -androstando [3,2-*c*] isoxazol-17 β -yl-acetate (4)*: Potassium carbonate (0.1 g) was added to a refluxing solution of 17 β -acetoxy-3-chloro-4-aza-5 α -androst-2-en-2-aldehyde (3) (0.1 g) in aldehyde-free ethanol (50 mL). Hydroxylamine hydrochloride (0.1 g) was added to the refluxing solution and further refluxed for 1 h. The reaction mixture was concentrated and then poured into ice-cold water (100 mL). The precipitate obtained was filtered, washed thoroughly with water, dried and crystallised from methanol to give the compound 4 m.p. 185°C. Yield 42.4%. Analysis: found (%) C 70.34, H 8.35, N 7.55; required C 70.36, H 8.43, N 7.82. UV max (MeOH): 262 nm. IR (KBr): 3189 (N—H stretch), 1734 cm^{-1} (ester). NMR (CDCl_3): δ 0.83 (s, 3H), 1.26 (s, 3H), 2.03 (s, 3H), 4.50 (m, 1H) and 7.87 ppm (s, 1H). EIMS m/z 357 (M^+).



4-Aza-5 α -androstando [3,2-*c*] isoxazol-17 β -yl-acetate (4)

*17a-Aza-D-homo-5-androsteno [17,16-*c*] isoxazol-3 β -yl acetate (6)*: Potassium carbonate (0.3 g) was added to a refluxing solution of 17-chloro-16-formyl-17a-aza-D-homo-5,16-androstadien-3 β -yl acetate (5) (0.3 g) in aldehyde-free ethanol (50 mL). Hydroxylamine hydrochloride (0.1 g) was added to the refluxing solution and was further refluxed for 1 h. The reaction mixture was concentrated and poured into ice-cold water. The precipitate obtained was filtered, washed thoroughly with water, dried and crystallized from methanol to give 6. m.p. 254°C. Yield 68.2%. Analysis: found (%) C 70.80, H 8.24, N 7.33; required C 71.33, H 8.16, N 7.56. UV max (MeOH): 265 nm, IR (KBr): 3125 cm^{-1} (N—H stretch), 2840 cm^{-1} (C—H stretch), 1730 cm^{-1} (ester). NMR (CDCl_3): δ 1.06 (s, 3H), 1.13 (s, 3H), 2.11 (s, 3H), 4.68 (m, 2H, 1H disappeared on D_2O exchange), 5.50 (m, 1H) and 8.03 ppm (s, 1H); EIMS: m/z 370 (M^+).

Anti-inflammatory activity: The screening was carried out using the corraegeenan rat paw oedema model¹³. The compounds were given orally as suspensions. The extent of inhibition of oedema was related to the dose

7a-Aza-D-homo-5-androsteno [17,16-c] isoxazol-3 β -yl acetate (6)

administered. For comparison, hydrocortisone was used as standard. Compounds 1, 3 and 5 which do not possess heterocycle fused to the azasteroid skeleton, were inactive in the dose range of 4–16 mg/kg. Whereas steroidal isoxazole 2 ($ED_{50} = 5.67$ mg/kg), 4 ($ED_{50} = 2.97$ mg/kg) and 6 ($ED_{50} = 11.00$ mg/kg) showed significant anti-inflammatory activity and were found to be more active than hydrocortisone ($ED_{50} = 13.49$) as shown in Table-1.

TABLE-1
ANTI-INFLAMMATORY ACTIVITY OF VARIOUS COMPOUNDS AND HYDRO
CORTISONE ON CARRAGEENAN-INDUCED PAW OEDEMA IN RATS (OBSERVED
180 MINUTES AFTER THE ADMINISTRATION OF CARRAGEENAN)

Compound	Dose (mg/kg)	No. of rats	Inhibition of oedema (%) \pm SEM	ED 50 (mg/kg)
1.	4.00	6	5.36 \pm 1.44	ND
	8.00	6	6.50 \pm 1.20	
	16.00	6	12.00 \pm 1.44	
2.	4.00	6	45.28 \pm 2.32	5.67
	8.00	6	55.36 \pm 1.28	
	16.00	6	61.48 \pm 1.68	
3.	4.00	6	12.36 \pm 0.96	ND
	8.00	6	16.00 \pm 7.39	
	16.00	6	21.51 \pm 2.12	
4.	4.00	6	52.00 \pm 1.44	2.97
	8.00	6	58.64 \pm 2.48	
	16.00	6	62.64 \pm 1.60	
5.	4.00	6	9.28 \pm 2.28	ND
	8.00	6	12.44 \pm 1.28	
	16.00	6	20.42 \pm 1.46	
6.	4.00	6	21.40 \pm 1.47	11.00
	8.00	6	42.00 \pm 1.92	
	16.00	6	55.06 \pm 2.02	
Hydrocortisone	4.00	6	18.80 \pm 1.65	13.49
	8.00	6	43.07 \pm 4.75	
	16.00	6	59.24 \pm 5.84	

Significance relative to control group data $P < 0.01$, ND: Not determinable.

ACKNOWLEDGEMENTS

Authors are thankful to the UGC, New Delhi for financial support and Panjab University for providing necessary facilities for the research work. Authors are also grateful to Burroughs Wellcome (India) Limited for generous supply of hydrocortisone.

REFERENCES

1. R. Hirschman, N.G. Steinberg, P. Buchschacher, J.H. Fried, G.J. Kent and M. Tishler, *J. Am. Chem. Soc.*, **85**, 120 (1963).
2. J.H. Fried, H. Mrozik, G.E. Arth, T.S. Bry, N.G. Steinberg, M. Tishler, R. Hirshman and S.L. Steelman, *J. Am. Chem. Soc.*, **85**, 236 (1963).
3. R. Hirschman, P. Buchschacher, N.G. Steinberg, J.H. Fried, R. Ellis, G.J. Kent and M. Tishler, *J. Am. Chem. Soc.*, **86**, 1520 (1964).
4. S.L. Steelman, E.R. Morgan and M.S. Glitzer, *Steroids*, **18**, 129 (1971).
5. D.P. Jindal and D. Pathak, *Eur. J. Med. Chem.*, **26**, 651 (1991).
6. R. Gupta, D. Pathak and D.P. Jindal, *Eur. J. Med. Chem.*, **31**, 241 (1996).
7. H. Singh, R.K. Malhotra and V.V. Parashar, *Tetrahedron Lett.*, 2587 (1973).
8. H. Singh, V. Kumar and D. Paul, *Indian J. Chem.*, **23B**, 1181 (1984).
9. H. Singh, M.R. Yadav and D.P. Jindal, *Indian J. Chem.*, **26B**, 95 (1987).
10. D.P. Jindal, M.R. Yadav, R.K. Sharma, V.K. Agrawal and H. Singh, *Indian J. Chem.*, **26B**, 100 (1987).
11. H. Singh and D. Paul, *Indian J. Chem.*, **12**, 1210 (1974).
12. C.C. Bolt, *Rec. Trav. Chim.*, **57**, 905 (1938).
13. C.A. Winter, E.A. Risley and G.W. Nuss, *Proc. Soc. Exp. Bio. Med.*, **111**, 544 (1960).

(Received: 6 February 1998; Accepted: 28 May 1998)

AJC-1491